Generic Detectnet Availability
Last updated on Jul 9, 2025.
Detectnet is a brand name of copper Cu 64 dotatate, approved by the FDA in the following formulation(s):
DETECTNET (copper cu-64 dotatate - solution;intravenous)
-
Manufacturer: CURIUM
Approval date: September 3, 2020
Strength(s): 4mL (1mCi/ML) [RLD]
Is there a generic version of Detectnet available?
No. There is currently no therapeutically equivalent version of Detectnet available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Detectnet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pet tracer for imaging of neuroendocrine tumors
Patent 10,159,759
Issued: December 25, 2018
Inventor(s): Kjaer Andreas & Knigge Ulrich & Højgaard Liselotte & Rasmussen Palle
Assignee(s): SOMSCAN APSThere is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
Patent expiration dates:
- August 23, 2032✓
- August 23, 2032
-
PET tracer for imaging of neuroendocrine tumors
Patent 10,383,961
Issued: August 20, 2019
Inventor(s): Kjaer Andreas & Knigge Ulrich & Højgaard Liselotte & Rasmussen Palle
Assignee(s): SOMSCAN APSThere is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
Patent expiration dates:
- July 2, 2033✓
- July 2, 2033
-
PET tracer for imaging of neuroendocrine tumors
Patent 11,160,888
Issued: November 2, 2021
Inventor(s): Kjaer Andreas & Knigge Ulrich & Højgaard Liselotte & Rasmussen Palle
Assignee(s): SOMSCAN APSThere is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
Patent expiration dates:
- August 23, 2032✓
- August 23, 2032
-
Radiolabeling and formulation for scale up of .SUP.64.Cu-DOTATATE
Patent 12,102,696
Issued: October 1, 2024
Inventor(s): Pipes; David et al.
Assignee(s): Curium US, LLC (St. Louis, MO)The present disclosure relates to methods to create a robust procedure capable of supplying commercial quantities of a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.
Patent expiration dates:
- September 3, 2041✓
- September 3, 2041
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 3, 2025 - NEW CHEMICAL ENTITY
- September 3, 2027 - FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
More about Detectnet (copper Cu 64 dotatate)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- FDA approval history
- Drug class: diagnostic radiopharmaceuticals
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
